AQR Arbitrage’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

AQR Arbitrage’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-502,062	Closed	-$20.5M	–	622
2024 Q2	$20.5M	Sell	502,062 -74,054	-13%	-$3.08M	0.53%	57
2024 Q1	$24.4M	Sell	576,116 -357,648	-38%	-$15M	0.85%	31
2023 Q4	$39.6M	Buy	+933,764	New	+$26.8M	1.6%	5
2020 Q4	–	Sell	-39,999	Closed	-$418K	–	1114
2020 Q3	$418K	Buy	+39,999	New	+$422K	0.02%	441

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

AQR Arbitrage's CERE Position: Q3 2024 in Review

AQR Arbitrage sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 502,062 shares — an estimated $20.5M sold.

AQR Arbitrage first reported a position in CERE in Q3 2020 and held it in 4 quarters. The position peaked at $39.6M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

AQR Arbitrage reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
AQR Arbitrage sold 502,062 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $20.5M.
AQR Arbitrage first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
AQR Arbitrage's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $39.6M in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on AQR Arbitrage's 13F filing for Q3 2024, filed 14 Nov 2024.